(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 3.75% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.87%.
Merck & Co's revenue in 2025 is $63,616,000,000.On average, 7 Wall Street analysts forecast MRK's revenue for 2025 to be $161,763,164,776,764, with the lowest MRK revenue forecast at $160,984,625,732,161, and the highest MRK revenue forecast at $162,127,174,217,453. On average, 7 Wall Street analysts forecast MRK's revenue for 2026 to be $168,825,109,782,476, with the lowest MRK revenue forecast at $165,997,676,636,638, and the highest MRK revenue forecast at $170,621,847,672,994.
In 2027, MRK is forecast to generate $177,884,866,724,975 in revenue, with the lowest revenue forecast at $173,663,857,881,140 and the highest revenue forecast at $184,341,171,737,733.